About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, three long-acting technologies, two oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, and SDC.
Featured
mRNA Technology Transfer Hub Programme
12 April 2022
LAPaL
14 February 2022
Access to Medicines Tracker
02 March 2020
VaxPaL
08 June 2021
Discover MedsPaL
MedsPaL, MPP’s medicines patents and licences database, is a free resource that provides information on the intellectual property status of selected patented essential medicines in low- and middle-income countries.
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in June 2022 (data as of 31 March 2022) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Impact Stories
How access to antiretrovirals is building the future
Key Publications
Twitter Feed
Unitaid @UNITAID
When Unitaid founded @MedsPatentPool, we envisioned an organisation that could unite partners to secure affordable, quality supply of life-saving medicines for LMICs. A decade later, #COVID19 truly validated the need for such a vital mechanism. Learn more: https://t.co/6whFHAk6kW https://t.co/5BphD3l61Q
Assistant Secretary Loyce Pace @HHS_ASGA
When we say, "equity" we mean doing business differently to build back better worldwide. That's why the U.S. has partnered with @WHO @MedsPatentPool mRNA tech transfer hub, Afrigen, on scientific training and exchange programs led by @BARDA and @NIH. Innovation + Access = IMPACT.
Tedros Adhanom Ghebreyesus @DrTedros
Last year, only 1 in 2 of children living with #HIV were receiving treatment. This is frankly a scandal, and a stain on our collective conscience. No child should be born with HIV or grow up with it, and no child with HIV should miss out on treatment. We have the tools. #AIDS2022 https://t.co/utccmsDdEH
